(Q43244850)

17 November 2017

Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury (English)

1 reference

17 November 2017

0 references

1 reference

3

1 reference

17 November 2017

Josef S Ozer

1

1 reference

17 November 2017

Raj Chetty

2

1 reference

17 November 2017

Joe Palandra

4

1 reference

17 November 2017

Yiqun Zhang

5

1 reference

17 November 2017

Anne Lanevschi

6

1 reference

17 November 2017

Nandan Koppiker

7

1 reference

17 November 2017

Bernard E Souberbielle

8

1 reference

17 November 2017

Shashi K Ramaiah

9

1 reference

17 November 2017

language of work or name

English

0 references

publication date

10 November 2009

1 reference

Regulatory Toxicology and Pharmacology

17 November 2017

1 reference

17 November 2017

56

1 reference

17 November 2017

3

1 reference

17 November 2017

237-246

1 reference

Hepatic manifestations of autoimmune rheumatic diseases

17 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Effect of moderate alcohol consumption on liver enzymes increases with increasing body mass index

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Protection by indomethacin against the lethality and hepatotoxicity of phalloidin in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Should we have more definitions of metabolic syndrome or simply take waist measurement?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Prevalence and long-term course of macro-aspartate aminotransferase in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Determination of serum uric acid using high-performance liquid chromatography (HPLC)/isotope dilution mass spectrometry (ID-MS) as a candidate reference method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Health consequences of visceral obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Increasing prevalence of the metabolic syndrome among u.s. Adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Evaluation of blood donors with elevated serum alanine aminotransferase levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Review article: The use of potentially hepatotoxic drugs in patients with liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Mechanisms of drug-induced liver injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Idiosyncratic drug-induced liver injury: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Comparison of alanine aminotransferase, white blood cell count, and uric acid in their association with metabolic syndrome: a study of Korean adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Idiosyncratic drug hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Controversies in transfusion medicine. Alanine aminotransferase screening of blood donors: pro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Retrospective analysis of transient elevations in alanine aminotransferase during long-term treatment with acetaminophen in osteoarthritis clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Drug-induced hepatotoxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Isoforms of alanine aminotransferases in human tissues and serum--differential tissue expression using novel antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Expression, purification, and initial characterization of human alanine aminotransferase (ALT) isoenzyme 1 and 2 in High-five insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Evaluation of commercially formulated aspartate aminotransferase and alanine aminotransferase activity determinations by the Scandinavian Committee on Enzymes and IFCC methods as modified for use with automated enzyme analysers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Identification of novel molecular candidates for acute liver failure in plasma of BALB/c murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Cytochrome c: a non-invasive biomarker of drug-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Calpain activation in plasma membrane bleb formation during tert-butyl hydroperoxide-induced rat hepatocyte injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Serum alanine aminotransferase in skeletal muscle diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

The predictivity of the toxicity of pharmaceuticals in humans from animal data--an interim assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Concordance of the toxicity of pharmaceuticals in humans and in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Pathological spectrum of liver diseases in sickle cell disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Serum uric acid is a determinant of metabolic syndrome in a population-based study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Novel prodromal biomarkers that are symptomatic of injury require histopathologic or clinical chemistry anchors to characterize activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

The current state of serum biomarkers of hepatotoxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

The regulation of alanine and aspartate aminotransferase by different aminothiols and by vitamin B-6 derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

The regulation of aminotransferase activity by carbamoyl-phosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Muscular exercise can cause highly pathological liver function tests in healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Successful translation of pharmacogenetics into the clinic: the abacavir example

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

AASLD position paper: the management of acute liver failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Relationship of serum alanine aminotransferase (ALT) to body mass index (BMI) in blood donors: the need to correct ALT for BMI in blood donor screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Effect of body mass and other factors on serum liver enzyme levels in men attending for well population screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Transaminase elevation on placebo during phase I trials: prevalence and significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

An official ATS statement: hepatotoxicity of antituberculosis therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

How can 'Hy's law' help the clinician?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Decreased hepatic ALT synthesis is an outcome of subchronic microcystin-LR toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Practical guidelines for diagnosis and early management of drug-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Hy's law: predicting serious hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Using controlled clinical trials to learn more about acute drug-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Cellular imaging predictions of clinical drug-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Potential role of regucalcin as a specific biochemical marker of chronic liver injury with carbon tetrachloride administration in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

The spectrum of hepatotoxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Drug-Induced Liver Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Tolerogenic role of Kupffer cells in immune-mediated adverse drug reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Hepatobiliary transporters and drug-induced cholestasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2009.11.001

10.1016/J.YRTPH.2009.11.001

7 January 2021

Identifiers

DOI

1 reference

17 November 2017

1 reference